In vitro differentiation of human intestinal organoids (HIOs) from pluripotent stem cells is an unparalleled system for creating complex, multicellular three-dimensional structures capable of giving rise to tissue analogous to native human tissue. Current methods for generating HIOs rely on growth in an undefined tumour-derived extracellular matrix (ECM), which severely limits the use of organoid technologies for regenerative and translational medicine. Here, we developed a fully defined, synthetic hydrogel based on a four-armed, maleimide-terminated poly(ethylene glycol) macromer that supports robust and highly reproducible in vitro growth and expansion of HIOs, such that three-dimensional structures are never embedded in tumour-derived ECM. We also demonstrate that the hydrogel serves as an injection vehicle that can be delivered into injured intestinal mucosa resulting in HIO engraftment and improved colonic wound repair. Together, these studies show proof-of-concept that HIOs may be used therapeutically to treat intestinal injury.
Synthetic hydrogels for human intestinal organoid generation and colonic wound repair
In vitro differentiation of human intestinal organoids (HIOs) from pluripotent stem cells is an unparalleled system for creating complex, multicellular three-dimensional structures capable of giving rise to tissue analogous to native human tissue. Current methods for generating HIOs rely on growth in an undefined tumour-derived extracellular matrix (ECM), which severely limits the use of organoid technologies for regenerative and translational medicine. Here, we developed a fully defined, synthetic hydrogel based on a four-armed, maleimide-terminated poly(ethylene glycol) macromer that supports robust and highly reproducible in vitro growth and expansion of HIOs, such that three-dimensional structures are never embedded in tumour-derived ECM. We also demonstrate that the hydrogel serves as an injection vehicle that can be delivered into injured intestinal mucosa resulting in HIO engraftment and improved colonic wound repair. Together, these studies show proof-of-concept that HIOs may be used therapeutically to treat intestinal injury.
Human pluripotent stem cells (hPSCs), such as embryonic stem cells (ESCs) 1 and induced pluripotent stem cells (iPSCs) 2 , are important cell sources for regenerative therapies and modelling of human diseases [3] [4] [5] . In vitro generation of human organoids from hPSCs offers unparalleled strategies for generating multicellular three-dimensional 3D structures recapitulating important features of epithelial and mesenchymal tissues [6] [7] [8] [9] . For example, human intestinal organoid (HIO) technology provides a powerful platform for functional modelling and repair of genetic defects in human intestinal development 10, 11 and the establishment of chronic disease models, such as inflammatory bowel disease 12 .
To generate HIOs, hPSCs are cultured and differentiated using growth factors in a Matrigel-coated substrate, giving rise to 3D intestinal spheroids that are collected and encapsulated within Matrigel for expansion into HIOs 13 . Matrigel is a heterogeneous, complex mixture of ECM proteins, proteoglycans and growth factors secreted by Engelbreth-Holm-Swarm mouse sarcoma cells 14 , which is required for 3D growth and expansion of HIOs. However, Matrigel suffers from lot-to-lot compositional and structural variability and, importantly, this tumour-derived matrix has limited clinical translational potential 15 . Indeed, a synthetic alternative to Matrigel that supports murine intestinal stem cell expansion and organoid formation has recently been reported 15 .
Here, we describe a completely synthetic hydrogel that supports in vitro generation of intestinal organoids from human ESC-and iPSCderived 3D spheroids without Matrigel encapsulation and promotes their engraftment and healing of murine colonic mucosal wounds. Hydrogel mechanical properties and adhesive ligand type were key parameters in engineering a synthetic ECM mimic that supported HIO viability, expansion and development. In addition, this synthetic hydrogel served as an injectable vehicle to deliver HIOs to intestinal wounds via a colonoscope resulting in organoid survival, engraftment and wound repair. The modular design of this synthetic matrix and the ability to deliver it via endoscopic techniques support the translational potential of this delivery platform for regenerative medicine and overcomes limitations associated with the use of Matrigel for hPSCbased organoid technologies.
Engineered hydrogels support HIO viability
We selected a hydrogel platform based on a four-arm poly(ethylene glycol) (PEG) macromer with maleimide groups at each terminus (PEG-4MAL) ( Supplementary Fig. 1a ), which exhibits high cytocompatibility and minimal toxicity and inflammation in vivo 16, 17 . Moreover, this hydrogel system offers significant advantages due to its well-defined structure, stoichiometric incorporation of biofunctional groups, and tunable reaction timescales for in situ gelation for in vivo applications 16, 17 .
PEG-4MAL macromers were functionalized with adhesive peptides and crosslinked in the presence of cells to generate PEG-4MAL hydrogels ( Supplementary Fig. 1a,b) . The mechanical properties of the hydrogel were tuned by varying polymer density ( Supplementary Fig. 1c,d) . We explored hydrogel formulations that supported the viability of ESC-derived HIOs that were first generated in Matrigel. After HIOs were grown in Matrigel, they were retrieved and encapsulated in PEG-4MAL hydrogel formulations ( Supplementary Fig. 1e ). As ECM mechanical properties influence epithelial cell behaviours 18 , we investigated the influence of hydrogel polymer density (3.5-6.0% wt/vol), which controls hydrogel mechanical properties ( Supplementary Fig. 1c,d ), on HIO viability at day 7 post-encapsulation ( Fig. 1a ). For reference, the mechanical properties of Matrigel (G = 78 Pa, G = 5.8 Pa) are in the range of the 3.5-4.0% PEG-4MAL formulations. These synthetic hydrogels were engineered to present a constant 2.0 mM RGD adhesive peptide (GRGDSPC) density and crosslinked with the protease-degradable peptide GPQ-W (GCRDGPQGIWGQDRCG). This adhesive peptide type and density were chosen as they have been shown to support epithelial cell viability and cyst formation in PEG-4MAL hydrogels 18 . The protease-degradable crosslinking peptide is necessary for celldependent matrix remodelling, cell migration and growth 18, 19 . HIOs embedded in 3.5% and 4.0% PEG-4MAL gels grew as cysts with an epithelium and central lumen, and maintained high viability for at least seven days in culture comparable with growth and viability of HIOs in Matrigel ( Fig. 1a ). Quantification of organoid viability area demonstrated no significant differences between HIOs embedded in 3.5% or 4.0% PEG-4MAL gels and HIOs in Matrigel (Fig. 1b ). In contrast, organoids encapsulated in 5.0% or 6.0% PEG-4MAL hydrogels exhibited significantly reduced viability at day 7 after encapsulation as compared with HIOs embedded in 3.5%, 4.0% PEG-4MAL gels or Matrigel ( Fig. 1a,b ). These results suggest polymer density-dependent effects on HIO survival within PEG-4MAL hydrogels. Although 3.5% PEG-4MAL hydrogels supported high HIO viability, this formulation was less mechanically stable compared with 4.0% PEG-4MAL hydrogels by seven days in culture. We therefore selected 4.0% PEG-MAL hydrogels for subsequent studies.
Interactions between adhesion receptors and ECM provide signals critical for cell survival, proliferation and differentiation 20 . Therefore, we examined whether the adhesive ligand type in the synthetic hydrogel affects HIO viability. Organoids were embedded within PEG-4MAL formulations of 4.0% polymer density and constant GPQ-W crosslinking peptide density but with different cysteine-terminated adhesive peptides (all at 2.0 mM; Fig. 1c,d) : RGD, laminin α1 chain-derived AG73 (CGGRKR-LQVQLSIRT) 21 , type I collagen-mimetic triple helical GFOGER (GYGGGP(GPP) 5 GFOGER(GPP) 5 GPC) 22 , and laminin α1 chainderived IKVAV (CGGAASIKVAVSADR) 23 . As the adhesive peptidefunctionalized macromer building blocks of the hydrogel are symmetric and form a regular mesh structure that is fully swollen, the adhesive peptide is uniformly distributed throughout the hydrogel network within the 'statistical average' of the mesh size (30-40 nm) . Furthermore, because of the small size of the PEG macromer arms and the swollen state of the gel, the mobility of the adhesive peptide is very limited and there is no effective clustering of the adhesive peptide 18 . Nevertheless, changes in adhesive peptide density at the nanoscale cannot be completely ruled out. Organoids encapsulated in RGDfunctionalized hydrogels maintained high viability for at least seven days after encapsulation (Fig. 1c,d and Fig. 2a ), similar to viability within Matrigel. In contrast, organoids encapsulated in PEG-4MAL hydrogels functionalized with AG73, GFOGER or IKVAV showed reduced viability at seven days post-encapsulation ( Fig. 1c,d ). Adhesion to RGD was required for HIO viability, as organoids encapsulated in hydrogels presenting an inactive scrambled peptide (RDG) showed reduced viability at seven days post-encapsulation ( Fig. 2b ). Finally, organoids exhibited low viability at seven days post-encapsulation in hydrogels crosslinked with non-degradable molecules (dithiothreitol (DTT), Fig. 2c ), demonstrating that prolonged survival of HIO requires a degradable matrix. Taken together, these results identify an engineered hydrogel formulation (4.0% polymer density, 2.0 mM RGD adhesive peptide, GPQ-W crosslinking peptide) that supports high viability for established HIOs, and which was used for all subsequent experiments.
Engineered hydrogel supports HIO development
We next examined HIO maintenance during culture in engineered hydrogels. Over several days in culture, established HIOs grew in size, changed shape, maintained a central lumen, and displayed epithelial budding at the interface with the hydrogel (Fig. 2d ). In addition, mesenchymal cells were observed migrating into the hydrogel, similar to HIOs maintained in Matrigel ( Fig. 2d,e ). To further characterize the intestinal epithelium of HIOs, we examined cell proliferation and apicobasal polarity in HIOs generated in Matrigel and those transferred to the engineered PEG-4MAL hydrogels. After seven days in culture, HIOs stained positive for Ki-67, indicating cell proliferation, demonstrated appropriate polarization of apical (ezrin) and basolateral (β-catenin) proteins, and localization of an epithelial tight junction protein (ZO-1) (ref. 24) ( Fig. 2f ,g). The staining patterns were similar when comparing HIOs maintained in PEG-4MAL hydrogel and Matrigel ( Fig. 2f ,g), demonstrating that the engineered PEG-4MAL hydrogel robustly supports HIO maintenance.
Engineered hydrogel generates HIOs from spheroids
The use of Matrigel to generate HIOs is a fundamental roadblock to the clinical translation of organoid technologies. We therefore examined whether the engineered PEG-4MAL hydrogel supports survival of hESC-derived intestinal spheroids and growth into HIOs without ever embedding in Matrigel. After four to five days of induction towards the intestinal lineage on a Matrigel-coated substrate, small 3D intestinal spheroids self-assemble and bud off from the cultured monolayer losing contact with Matrigel. Detached, floating mCherryexpressing intestinal spheroids were collected from the media and encapsulated in PEG-4MAL hydrogels formulated over a range of polymer densities (3.5-12.0%) ( Supplementary Fig. 1f ) to examine a range of mechanical properties ( Supplementary Fig. 1c,d ). All of these hydrogels were engineered to present 2.0 mM RGD adhesive peptide and crosslinked with GPQ-W. Spheroids embedded in 3.5% Scale bar, 500 µm. (b) Percentage of total organoid area stained for live or dead (mean ± s.e.m.) after seven days of encapsulation (n = 5 organoids analysed for all groups, except n = 6 organoids analysed for the 4.0% group). (c) Transmitted light and fluorescence microscopy images of HIOs cultured in 4.0% PEG-4MAL hydrogels functionalized with different adhesive peptides or Matrigel. HIO viability was assessed at seven days after encapsulation. Scale bar, 500 µm. (d) Percentage of total organoid area stained for live or dead (mean ± s.e.m.) after 7 days of encapsulation (n = 5 organoids analysed for all groups, except n = 6 organoids analysed for AG73 and Matrigel groups). For b,d, one-way ANOVA with Tukey's multiple comparisons test showed significant differences between 4.0% PEG-4MAL or Matrigel and 5.0 or 6.0% PEG-4MAL (b), and between PEG-4MAL-RGD or Matrigel and PEG-4MAL-GFOGER or -IKVAV (d). ( * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001.) In a-d, three independent experiments were performed and data are presented for one of the experiments. Every independent experiment was performed with six gel samples per experimental group (PEG-4MAL, Matrigel). Source data are available in Supplementary Table 1 . and 4.0% PEG-4MAL maintained viability at 2 h after encapsulation and grew into larger structures reminiscent of organoids with high viability at five days after encapsulation ( Fig. 3a) . In contrast, spheroids encapsulated in 8.0% and 12.0% PEG-4MAL hydrogels displayed significantly lower viability at 2 h post-encapsulation when compared with spheroids embedded in 3.5% or 4.0% PEG-4MAL ( Fig. 3a) . Consistent results were observed between hESC-and hiPSC-derived spheroids ( Supplementary Fig. 2 ). hiPSC-derived intestinal spheroids encapsulated in 4.0% PEG-4MAL grew into organoids with high viability at five days after encapsulation and developed over three weeks into HIOs similar to spheroids encapsulated in Matrigel ( Supplementary Fig. 2a,b ). In contrast, hiPSC-derived spheroids encapsulated in 8.0% PEG-4MAL hydrogels showed very low viability by one day post-encapsulation ( Supplementary Fig. 2c ). The strong dependence of spheroid and HIO viability on hydrogel polymer density suggests that the mechanical properties of these synthetic matrices regulate organoid survival. However, varying polymer density also alters the mesh size for these networks, which can impact diffusional properties of the hydrogel. It is not possible to uncouple mechanical properties from diffusional properties over the full range of polymer densities (3.5-12.0%) examined in this study. However, we compared organoid viability and size in RGDfunctionalized hydrogels from different macromer sizes (relative molecular mass of 20,000 versus 40,000) but different polymer densities (4.0% versus 8.0%) and engineered to have equivalent crosslinking densities ( Supplementary Fig. 3a -c). These hydrogels exhibit different diffusive characteristics/permeability caused by the differences in macromer arm length but have equivalent mechanical properties due to equivalent crosslinking densities 18 . ESC-derived spheroids developed normally into HIOs after five days of encapsulation in either hydrogel formulation showing no differences in HIO viability ( Supplementary Fig. 3a,b ), and no differences in projected area and longest distance between two points along the projected area (Feret diameter; Supplementary  Fig. 3c ). These results suggest that polymer density-dependent spheroid survival and development into HIOs is related to hydrogel mechanical properties. Furthermore, we evaluated the role of known mechanotransduction pathways on spheroid survival. Inhibition of nuclear translocation of yes-associated protein (YAP), which has been implicated in mechanotransduction and regulation of intestinal stem cell self-renewal 15 , using verteporfin resulted in significant cell death for spheroids encapsulated in PEG-4MAL hydrogels compared with vehicle control ( Supplementary Fig. 3d and Rho-associated kinase 25, 26 , respectively, resulted in dosedependent increases in apoptosis and spheroid death at one day post-encapsulation ( Supplementary Fig. 3d-f ). These results provide a preliminary indication that YAP and cellular contractility are important in the initial stages of human intestinal spheroid survival and development into HIOs. We next analysed HIO generation from ESC-derived spheroids cultured within the engineered synthetic matrix (4.0% polymer density, 2.0 mM RGD, GPQ-W crosslinker). Intestinal spheroids cultured within PEG-4MAL hydrogels grew in size over seven days as shown by a twofold increase in projected area (Fig. 3b ) and a 1.4-fold increase in Feret diameter ( Fig. 3c ) as compared with the day of encapsulation (day 0; Fig. 3b,c ). There were no differences in spheroid area, diameter or growth rates between spheroids cultured in PEG-4MAL hydrogels and Matrigel (Fig. 3b,c) . As we observed for established HIOs, spheroids changed shape during expansion and displayed epithelial budding at the interface with the hydrogel and cell outgrowths migrating into the hydrogel ( Supplementary Fig. 2d ). During HIO development, spheroids cultured in PEG-4MAL hydrogels were passaged in a similar manner as previously described for Matrigel 13, 27 . Immunostaining analyses at 21 days post-encapsulation demonstrated that organoids generated in engineered PEG-4MAL hydrogels were proliferating as shown by Ki-67 labelling, had polarized distribution of apical ezrin and basolateral β-catenin, and expressed ZO-1 in the apical junctional complex (Fig. 3d,e ). These staining patterns were identical to organoids generated in Matrigel. Quantitative polymerase chain reaction with reverse transcription (RT-qPCR) confirmed that expression levels of pluripotency (OCT4), endoderm (FOXA2), and epithelial junction (ZO1, ECAD and CLDN2) markers in hydrogelencapsulated spheroids were comparable to those embedded in Matrigel and had similar behaviours during early time points while developing into HIOs ( Supplementary Fig. 4 ). Finally, to test whether these synthetic matrices are suitable for the culture of other human organoids, we embedded human lung organoids (HLOs) 28, 29 in engineered PEG-4MAL hydrogels ( Supplementary Fig. 5 ). HLOs cultured in PEG-4MAL hydrogels maintained high viability seven days after encapsulation ( Supplementary Fig. 5a ), and demonstrated an organized lung epithelium (ECAD), lumen formation, and specific markers for lung epithelium (NKX2.1) and airway basal cells (P63) as assessed by immunostaining analyses ( Supplementary Fig. 5b) 28, 29 . Taken together, these results demonstrate that this fully synthetic hydrogel supports the generation of ESC-and iPSC-derived HIOs from the intestinal spheroid stage without the use of Matrigel, and has the potential to be adapted for the generation of different human organoids.
Hydrogel-generated HIOs differentiate in vivo
We next examined the potential of hydrogel-grown HIOs to differentiate into mature intestinal tissue in vivo as previously demonstrated 24, 30 . mCherry-expressing spheroids that were embedded and grown within engineered PEG-4MAL hydrogels or in Matrigel for three weeks were recovered from their respective matrix and implanted under the kidney capsule of immunocompromised NSG mice (Fig. 4 ). In addition, HIOs grown in Matrigel for two weeks and then transferred and cultured within PEG-4MAL hydrogels for one week (hydrogel-maintained) were implanted under the kidney capsule ( Fig. 4a,b,d) . After 12 weeks, implanted kidneys contained mCherry-expressing HIOs that were 10-to 40-fold larger in area than at the time of implantation (Fig. 4a,b) , consistent with previous reports. Dissected PEG-4MAL-generated HIOs showed differentiated intestinal epithelium that resembled mature human intestine with crypt-villus architecture and underlying lamina propria, muscularis mucosae and submucosa 24 , with structured collagen fibres (trichrome) and presence of differentiated goblet cells (alcian blue), comparable to Matrigel-generated and hydrogel-maintained organoids (Fig. 4c,d) . Polarized epithelial differentiation of PEG-4MAL hydrogel-generated HIOs was demonstrated by immunostaining for β-catenin, ezrin, ZO-1 and ECAD (Fig. 5a ). Additionally, PEG-4MAL-generated organoid epithelium showed localized cell proliferation (Ki-67) at the base of the crypt where the intestinal stem cells reside, and expressed characteristic markers for the intestinal epithelial protein CDX2, enteroendocrine cells (CHGA), goblet cells (MUC2) and tuft cells (DCLK1) (ref. 31 ). Furthermore, PEG-4MAL-generated HIOs expressed PDX1, demonstrating a duodenum regional identity (Fig. 5a) 13 . Expression was comparable to Matrigel-generated organoids and hydrogel-maintained organoids (Fig. 5b) . These results demonstrate that HIOs generated in the engineered synthetic (e) Images of mucosal wounds at 1 day (prior to injection) or 5 day post-injury in murine colon as seen through the colonoscope camera. Mucosal wound area at 5 days post-injury was normalized to day 1 (prior to injection) values (mean ± s.e.m.). Five colonic wounds per mouse were analysed and averaged (n = 4 mice per condition). One-way ANOVA with Tukey's multiple comparisons test showed significant difference between hydrogel-grown HIOs in hydrogel (filled red circles) or Matrigel-grown HIOs in hydrogel (filled blue squares) and saline-injected HIOs (filled brown triangles), hydrogel alone (filled purple lozenges), or no injection group (black crosses) ( * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001). Scale bars, 500 µm. Two independent experiments were performed and data are presented for one of the experiments. Experiments performed with four mice per experimental group (five colonic wounds/injections per mouse; a-e). Source data are available in Supplementary Table 1 .
matrix can differentiate into mature intestinal tissue in an in vivo environment to the same extent as HIOs generated within Matrigel. These findings establish engineered synthetic PEG-4MAL hydrogels as a robust alternative to Matrigel with significant implications for translational medicine.
Hydrogels as a HIO delivery vehicle to heal colonic wounds
A key advantage of the PEG-4MAL hydrogel system is control over gelling time, so that the hydrogel components can be injected as a solution that gels in situ 17 . We therefore explored the use of the engineered hydrogel as a delivery vehicle for HIOs into murine intestinal mucosal wounds using a murine colonoscope. HIOs generated in PEG-4MAL hydrogels or Matrigel were recovered from their matrix, mixed with the hydrogel precursor solution, and injected at the site of mechanically induced mucosal wounds in the distal colon of immunocompromised mice ( Fig. 6a and Supplementary Fig. 6a) 32 . Wound closure was evaluated using a colonoscope, and fluorescence imaging showed localized expression of mCherry-positive tissue at the wound site five days post-injection ( Fig. 6b ). Immunostaining at four weeks post-injection demonstrated that HIO delivery via the synthetic hydrogel resulted in HIO engraftment into host intestinal epithelial tissue as shown by positive staining for human nuclei (NUMA) to detect HIOs generated in either the PEG-4MAL hydrogel or Matrigel (Fig. 6c ). Importantly, no staining was evident for no-injection control, hydrogel alone and HIOs injected in saline (Fig. 6c ), demonstrating that the hydrogel delivery vehicle is required for HIO engraftment and wound repair. Examination of HIO engraftment at the wound edge demonstrated staining for human cells adjacent to host tissue that stained negative for human markers. Engraftment of human cells into the colonic wound was also confirmed by positive staining for human mitochondria (HUMIT; Supplementary Fig. 6b ). Furthermore, colonic wounds treated with HIOs delivered with hydrogel showed positive staining for an OLFM4 probe specific to human cells at the base of the crypt-like domain ( Fig. 6d and Supplementary Fig. 6c ), a pattern consistent with staining in the normal adult human colon ( Supplementary Fig. 6c ), which is also consistent with previous reports of human OLFM4 protein and/or messenger RNA localization [33] [34] [35] . In addition, several negatively stained human cryptlike domains were adjacent to mouse intestinal crypts that stained positive for a mouse-specific Lgr5 probe ( Supplementary Fig. 6d ) via in situ hybridization 36 . These observations were compared with control tissue sections from immunocompromised mice that did not undergo colonic injuries or received HIO injections ( Fig. 6d and Supplementary Fig. 6d ).
We also examined whether delivered HIOs promote colonic mucosal wound repair (Fig. 6e) . Strikingly, delivery of HIOs to colonic wounds using the hydrogel carrier significantly increased wound closure compared with untreated wounds and wounds treated with hydrogel alone or HIOs without the hydrogel carrier ( Fig. 6e) . No differences were observed in wound closure between HIOs generated in the synthetic hydrogels and Matrigel. Taken together, these results demonstrate that the engineered PEG-4MAL hydrogel serves as an injectable delivery vehicle that supports localized HIO engraftment in colonic mucosal wounds and enhances wound closure. These findings establish the clinical translational potential of the synthetic hydrogel as an in vivo delivery vehicle for hPSC-derived HIOs and provide proof-of-concept that HIOs may be used therapeutically to treat intestinal injury or disease.
In this study, we engineered a completely synthetic hydrogel that supports in vitro generation of intestinal organoids from hPSCderived spheroids without the need of Matrigel encapsulation. Both mechanical and biochemical properties of the synthetic ECM were important to intestinal organoid formation, and we identified an optimal formulation that supports intestinal spheroid survival, expansion and epithelial differentiation into HIOs and differentiation into mature intestinal tissue in vivo to similar levels as Matrigel. In addition, we showed that this synthetic matrix supports the development of other human organoids such as HLOs. The requirement for specific mechanical and cell adhesive properties in the synthetic matrix is consistent with previous work showing that epithelial cell cyst growth, polarization and lumen formation are restricted to a narrow range of ECM elasticity and that adhesive peptide type regulates apicobasal polarity and lumenogenesis during epithelial morphogenesis in 3D cultures 18 . Interestingly, the mechanical properties and protease degradation characteristics that supported hPSC-derived organoids in this study are different from those recently identified for murine Lrg5 + intestinal stem cell growth and organoid formation 15 , which involved more complex, mechanically dynamic properties, and suggest differences between these two organoid sources. This fully synthetic matrix addresses major limitations of Matrigel associated with lot-to-lot compositional and structural variability and its tumour-derived nature that severely restrict scale-up applications and clinical translation.
We also established the use of the engineered hydrogel as a delivery vehicle for HIOs to murine intestinal mucosal wounds using a murine colonoscope. Although other studies have focused on the delivery of murine intestinal organoids into the colonic lumen as a suspension 7 , we showed that absence of a delivery vehicle reduces HIO engraftment at the implantation site. Injection of hydrogel liquid precursors and HIOs to mucosal wounds resulted in an in situ polymerized hydrogel that supported localized organoid engraftment and enhanced wound repair. Therefore, this delivery strategy forms a basis for the development of HIO-based therapies to treat gastrointestinal diseases in humans involving intestinal epithelial wounds (for example, inflammatory bowel disease). Furthermore, the modular nature of this hydrogel platform allows for the adaptation to in vitro generation and in vivo delivery of other human PSC-derived organoids (for example, lung) for regenerative medicine.
METHODS

Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3632 METHODS Immunofluorescence analysis. For immunofluorescence labelling of frozen sections from colon, HIOs, kidney capsule implanted-HIOs or HLOs, these were fixed with 3.7% (w/v) paraformaldehyde at room temperature for 15 min, followed by 0.5% (w/v) Triton X-100 for 5 min. Primary antibody incubation was performed overnight at a 1:100 dilution, unless stated otherwise. Secondary antibody incubation was performed for 1 h at a 1:2,000 dilution. Detailed information on the antibodies used including their resources (company names, catalogue numbers) and dilutions are provided in the Reporting Summary.
Differentiation of hPSCs into intestinal spheroids or HLOs.
All work using human pluripotent stem cells was approved by the University of Michigan Human Pluripotent Stem Cell Oversight Committee (HPSCRO). Stem cell lines are routinely monitored for chromosomal karyotype, pluripotency (using a panel of antibody and RT-qPCR markers), and for the ability to undergo multi-lineage differentiation. For intestinal spheroid generation, mycoplasma-free human ES cells (H9, NIH registry no. 0062) and iPS cells (line 20.1, source as previously described 13 ) were cultured on Matrigel-coated plates and differentiated into intestinal tissue as previously described 13 . Floating spheroids present in the cultures on day 4 and day 5 of mid/hindgut induction were harvested for use in subsequent experiments. In some experiments, hESCs expressing a constitutively active H2BmCherry fluorescent reporter were used. This line was generated by infecting hESCs with a lentivirus containing PGK-H2BmCherry, which was a gift from M, Mercola (Addgene plasmid no. 21217) (ref. 37). For HLO generation, human ES cells (UM63-1, NIH registry no. 0277) were maintained, differentiated and expanded into HLOs as previously described 29 .
Hydrogel formation and in vitro intestinal spheroid/HIO. To prepare PEG hydrogels, PEG-4MAL macromer (MW 22,000 or 44,000; Laysan Bio) was dissolved in 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer (20 mM in DPBS, pH 7.4). Adhesive and GPQ-W crosslinking peptides were custom synthesized by AAPPTec. Adhesive peptides RGD (GRGDSPC), AG73 (CGGRKRLQVQLSIRT), GFOGER (GYGGGP(GPP) 5 GFOGER(GPP) 5 GPC), IKVAV (CGGAASIKVAVSADR) and RDG (GRDGSPC) were dissolved in HEPES at 10.0 mM (5× final ligand density) and mixed with PEG-4MAL at a 2:1 PEG-4MAL/ligand ratio to generate functionalized PEG-4MAL precursor. Bis-cysteine crosslinking peptide GPQ-W (GCRDGPQG↓IWGQDRCG; ↓ denotes enzymatic cleavage site) or non-degradable crosslinking agent DTT (1,4-dithiothreitol; 3483-12-3, Sigma) was dissolved in HEPES at a density corresponding to 1:1 maleimide/cysteine ratio after accounting for maleimide groups reacted with adhesive peptide. For HIO encapsulation, spheroids were embedded and expanded in Matrigel for up to 30 days. Resulting HIOs were dislodged from the Matrigel and resuspended at 5× final density (final density: 2-4 HIOs per hydrogel) in intestine growth medium 38 and kept on ice. For human intestinal spheroid encapsulation, spheroids were harvested immediately after differentiation and were resuspended at 5× final density (final density: 20-30 spheroids per hydrogel) in intestine growth medium and kept on ice. For HLO encapsulation, the HLOs were dislodged from the Matrigel and resuspended at 5× final density (final density: 2-4 HLOs per hydrogel) in foregut growth medium 27, 28 and kept on ice. To form hydrogels, adhesive peptide-functionalized PEG-4MAL macromer, cells and crosslinking peptide were polymerized for 20 min before addition of intestine growth medium. Matrigel-generated hPSC-derived HIOs were generated and cultured as described previously 13, 38 . Passaging of HIOs cultured in PEG-4MAL hydrogels was performed similarly to tissue embedded in Matrigel, as previously described 27, 38 . Briefly, HIOs were dislodged from the PEG-4MAL hydrogel, transferred to a sterile Petri dish, and manually cut into halves using a scalpel. HIO halves were resuspended at 5× final density (final density: 2-4 HIOs per hydrogel) in intestine growth medium 38 and mixed with hydrogel precursor solutions to form PEG-4MAL hydrogels. HIOs were passaged up to three times over the course of three weeks. Matrigel-generated HIOs were passaged as described previously 13, 38 . Sample size was established as at least four hydrogels per condition with the premise that an outcome present in four different hydrogels under a specific condition will reveal the population behaviour submitted to this given condition.
A detailed protocol for generating the hydrogel and embedding HIOs can be found at the Protocol Exchange: http://dx.doi.org/10.1038/protex.2017.098.
Hydrogel characterization. The storage and loss moduli of hydrogels were assessed by dynamic oscillatory strain and frequency sweeps performed on a MCR 302 stress-controlled rheometer (Anton Paar) with a 9-mm-diameter, 2 • cone, and plate geometry. Oscillatory frequency sweeps were used to examine the storage and loss moduli (ω = 0.5-100 rad s −1 ) at a strain of 2.3%.
Viability assay and quantification. PEG-4MAL gels were incubated in 2 µM Calcein-AM (live; Life Technologies), and 1 µM TOTO-3 iodide (dead; Life Technologies) in growth medium for 1 h. Samples were imaged using an Axiovert 35, Zeiss microscope. Quantification of viability was performed by calculating the percentage of the total projected area of a spheroid/organoid that stained positive for the live or dead stain using ImageJ (National Institute of Health, USA). The results are representative of three independent experiments performed with six PEG-4MAL/Matrigel gel samples per experimental group.
Inhibition of mediators of mechanotransduction. Inhibition of YAP, myosin II
or Rho-associated kinase was performed using verteporfin (SML0534, Sigma), blebbistatin (203389, Calbiochem) and Y-27632 (688002, Calbiochem), respectively, by adding 10 or 30 µM to the intestine growth medium 20 min after spheroid encapsulation in hydrogel. Cell apoptosis/death was assessed 1 day after encapsulation using Annexin V/Dead Cell Apoptosis Kit (A13201, ThermoFisher). Samples were imaged using an Axiovert 35, Zeiss microscope. The results are representative of one experiment performed with 12 PEG-4MAL hydrogel samples per experimental group.
RT-qPCR.
Total RNA from hESC day 0 spheroids or HIOs grown in PEG-4MAL hydrogels or Matrigel was extracted using the MagMax RNA isolation system and MagMax-96 total RNA isolation Kit (AM1830, ThermoFisher Scientific). cDNA was synthesized using the SuperScript VILO cDNA Synthesis Kit (11754-250, ThermoFisher Scientific). RT-qPCR was carried out using the QuantiTect SYBR Green PCR Kit (204145, Qiagen). Relative gene expression was plotted as arbitrary units using the formula: [2 ∧ (housekeeping gene Ct − gene of interest Ct)] × 10,000. Primer sequences for RT-qPCR are provided in Supplementary Table 2 . Kidney capsule implantation. Organoids were implanted under the kidney capsule of male NOD-scid IL2Rg-null (NSG) mice (Jackson Laboratory) as previously described 24 . Briefly, mice were anaesthetized using 2% isoflurane. The left flank was shaved and sterilized using chlorhexidine and isopropyl alcohol. A left-flank incision was used to expose the kidney. HIOs were manually placed in a subcapsular pocket of the kidney using forceps. An intraperitoneal flush of Zosyn (100 mg kg −1 ; Pfizer) was administered prior to closure in two layers. The mice were euthanized and the transplant retrieved after 12 weeks. The results are representative of one experiment performed with three mice per condition (one organoid implanted per kidney capsule). Sample size was established as three with the premise that an outcome present in three different animals under a specific condition will reveal the population behaviour submitted to this given condition. No statistical method was used to predetermine sample size.
Colonic mucosal wound and HIO injections. NSG mice were anaesthetized by intraperitoneal injection of a ketamine (100 mg kg −1 )/xylazine (10 mg kg −1 ) solution. A high-resolution miniaturized colonoscope system equipped with biopsy forceps (Coloview Veterinary Endoscope, Karl Stortz) was used to biopsy-injure the colonic mucosa at 3-5 sites along the dorsal artery. Wound size averaged approximately 1 mm 2 . HIO injection was performed on day 1 after wounding with the aid of a custom-made device comprising a 27-gauge needle (OD: 0.41 mm) connected to a small tube ( Supplementary Fig. 6a ). Endoscopic procedures were viewed with high-resolution (1,024 × 768 pixels) live video on a flat-panel colour monitor. The results are representative of two independent experiments performed with four mice per condition (five colonic wounds/injections per mouse) according to our previous experience with this model. Wound closure quantification. Mice were anaesthetized by intraperitoneal injection of a ketamine (10 g l −1 )/xylazine (8 g l −1 ) solution (10 µl g −1 body weigh). To create mucosal injuries in the mouse colon and to monitor their regeneration, a high-resolution colonoscopy system was used. Each wound region was digitally photographed at day 1 and day 5, and wound areas were calculated using ImageJ (National Institute of Health, USA). In each experiment, three to four lesions per mouse were examined.
In situ hybridization (ISH). ISH for mouse Lgr5 expression was performed on frozen sections fixed with 4% paraformaldehyde. Slides were permeabilized with proteinase K (3115887001, Sigma-Aldrich) for 30 min at 37 • C, washed with Saline-Sodium Citrate buffer and then acetylated at room temperature for 10 min. A prehybridization step was performed for 1 h at 37 • C in a humidified chamber. A DIG-labelled riboprobe diluted in hybridization buffer was incubated overnight at 68 • C. The slides were then washed and blocked for 1 h at room temperature followed by incubation with DIG antibody (11093274910, Sigma-Aldrich) overnight at 4 • C. The developer solution (11681451001, Roche) was incubated for 72 h until the Lgr5 + cells became evident. ISH for OLFM4 expression was performed using the RNAscope 2.5 HD manual assay with brown chromogenic detection (Advanced Cell Diagnostics) as per the manufacturer's instructions. The human 20-base-pair OLFM4 probe was generated by Advanced Cell Diagnostics targeting 20 base pairs within 1111-2222 of OLFM4 (gene accession NM_006418.4) and is commercially available. The results are representative of two independent experiments performed with four mice per condition (five colonic wounds/injections per mouse).
Statistics and reproducibility.
All experiments were performed three or more times independently under similar conditions, except experiments shown in Fig. 6 and Supplementary Fig. 6 , which were performed twice. Plots shown in Figs 1b,d, 3a -c and 6e, and Supplementary Figs 1c,d, 3 (Figs 1b,d, 3a and 6e) , two-way repeated measures ANOVA (Fig. 3b,c) , and unpaired t-test with Welch's correction (Supplementary Figs 3b,c and 4) as described in the figure legends. P values of statistical significance are represented as * * * * P < 0.0001, * * * P < 0.001, * * P < 0.01, * P < 0.05. Figs 1b,d, 3a-c and 6e , and Supplementary  Figs 1c,d, 
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical method was used to predetermine sample size. For in vitro experiments, sample size was established as at least 4 hydrogels per condition (20-30 spheroids/hydrogel or 2-4 HIOs or HLOs/hydrogel) with the premise that an outcome present in all hydrogels under a specific condition will reveal the population behavior submitted to this given condition. For in vivo experiments, sample size was established as 3 with the premise that an outcome present in 3 different animals under a specific condition will reveal the population behavior submitted to this given condition.
Data exclusions
Describe any data exclusions. The exclusion criteria was to exclude data from mice euthanized because of sickness. No animal was excluded from studies.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For all experiments, one tube containing human intestinal spheroids, HIOs or HLOs was vortexed prior to mixing with different hydrogel precursor solutions, ensuring a random allocation of the biological tissue into the experimental groups. No randomization was used during inhibitor treatment or for animal experiments.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was performed during outcome assessment. The researchers that performed the in vivo experiments were not the researchers that processed and analyzed the tissue resulting from these experiments.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Image acquisition of immunofluorescence experiments was performed using LAS X (Leica Microsystems, Inc.) Quantification of spheroid/HIO viability and size parameters were performed using ImageJ 1.50b (National Institute of Health, USA). RT-qPCR data analysis was performed using Microsoft Excel 2016 (Microsoft Corp.). All statistical analyses were performed using GraphPad Prism 6.0.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used.
